Editor's Corner

Cancer Genetics makes strides in $14M deal for Response Genetics

Cancer Genetics got approval from a U.S. bankruptcy court in Delaware to purchase Response Genetics, almost two months after the company emerged as the highest bidder in an auction sale of Response's long-beleaguered business.

Illumina expands in China with cancer Dx deal

Illumina is joining forces with China's Amoy Diagnostics to create next-generation sequencing cancer tests for the Chinese clinical market, expanding its footprint in the country while strengthening its commitment to developing innovative technology for the disease.

Quest's Focus Diagnostics gets FDA clearance to add additional strains to its flu test

Focus Diagnostics, a unit of Quest Diagnostics, announced that it has the FDA's 510(k) clearance for its Simplexa Flu A/B & RSV Direct Kit for 46 additional influenza A and B virus strains and 7 additional respiratory syncytial virus strains.

Illumina stock tanks after profit warning

Illumina issued a profit warning due to poor sales of its NextSeq Series Desktop Sequencer as well as weakness in Europe and Japan, sending its stock tumbling 10% for the day. The company expects earnings per share to fall below consensus expectations, consistent with a 3% revenue shortfall.

Quest and Inovalon launch patient analytics tool for healthcare providers

Quest Diagnostics has been working hard to diversify its offerings, beefing up its presence in diagnostics as it delivers on plans for growth. In its latest move, the company is teaming up with health IT outfit Inovalon to roll out a cloud-based analytics platform for healthcare providers.


From Our Sister Sites


While working to catch up with other vaccine developers in the race for a respiratory syncytial virus (RSV) vaccine, San Francisco-based Vaxart this week unveiled data demonstrating its candidate's ability to create a "substantial" immune response in a preclinical challenge model.


An FDA warning letter found that for years, Dr. Reddy's Laboratories was testing drug batches in a laboratory that the FDA was never told existed and often shipped to the U.S. products that had repeatedly failed tests for impurities.